ABSTRACT

Signs of physical dependence as a consequence of long-term drug use and a moderate abuse liability limit benzodiazepine clinical usefulness. Growing evidence suggests a role for voltage-gated calcium channel (VGCC) regulation in mediating a range of chronic drug effects from drug withdrawal phenomena to dependence on a variety of drugs of abuse. High voltage-activated (HVA) calcium currents were measured in whole-cell recordings from acutely isolated hippocampal CA1 neurons after a 1-week flurazepam (FZP) treatment that results in withdrawal-anxiety. An ∼1.8-fold increase in Ca²⁺ current density was detected immediately after and up to 2 days but not 3 or 4 days after drug withdrawal. Current density was unchanged after acute desalkyl-FZP treatment. A significant negative shift of the half-maximal potential of activation of HVA currents was also observed but steady-state inactivation remained unchanged. FZP and diazepam showed use- and concentration-dependent inhibition of Ca²⁺ currents in hippocampal cultured cells following depolarizing trains (FZP, IC₅₀ = 1.8 μM; diazepam, IC₅₀ = 36 μM), pointing to an additional mechanism by which benzodiazepines modulate HVA Ca²⁺ channels. Systemic preinjection of nimodipine (10 mg/kg), an L-type (L)-VGCC antagonist, prevented the benzodiazepine-induced increase in α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPA)-mediated miniature excitatory postsynaptic current in CA1 neurons 2 days after FZP withdrawal, suggesting that AMPAR potentiation, previously linked to withdrawal-anxiety may require enhanced L-VGCC-mediated Ca²⁺ influx. Taken together with prior work, these findings suggest that enhanced Ca²⁺ entry through HVA Ca²⁺ channels may contribute to hippocampal AMPAR plasticity and serve as a potential mechanism underlying benzodiazepine physical dependence.

Benzodiazepines, a group of positive allosteric modulators of GABA_A receptors, are widely prescribed for the treatment of anxiety, insomnia, and seizure disorders. However, widespread legitimate prescription of benzodiazepines increases the proportion of patients who develop dependence. Reducing the dose or abrupt discontinuation of treatment may result in withdrawal symptoms, such as anxiety, agitation, sleep disturbances, and seizures or delirium after high-dose use (Griffiths and Johnson, 2005). Although it is controversial whether physical dependence can reinforce self-administration, leading to benzodiazepine dependence or addiction (Griffiths and Weerts, 1997), understanding the neuronal mechanisms underlying the consequences of long-term drug treatment may improve the clinical usefulness of benzodiazepines.

Prolonged exposure to GABA_A receptor-positive allosteric modulators, including ethanol and barbiturates, as well as...
other drugs of abuse has been reported to enhance high voltage-activated calcium channels (HVAs), predominantly L-type voltage-gated calcium channel (L-VGCC) expression (Walter and Messing, 1999; Katsura et al., 2002, 2005, 2007; Rajadhyaksha and Kosofsky, 2005; Shibasaki et al., 2007). Benzodiazepine administration can similarly regulate VGCC expression. For example, [3H]diltiazem binding sites were up-regulated in mouse cortical cultures, concomitant with an increase in L-VGCC subunit expression after 3-day exposure of mouse cortical cultures to 1,4- or 1,5-benzodiazepines and in diazepam (DZP)-treated mice exhibiting withdrawal signs (Katsura et al., 2007). Moreover, benzodiazepines can directly inhibit L-VGCC-mediated Ca\(^{2+}\) influx and HVA currents (Taft and DeLorenzo, 1984; Gershon, 1992; Reuveny et al., 1993; Ishizawa et al., 1997), raising the possibility that chronic benzodiazepine administration in vivo can modulate VGCC function.

VGCCs have been implicated in mediating synaptic plasticity associated with dependence on a wide range of central nervous system stimulants and depressants (Whittington and Little, 1993; Pourmotabbed et al., 1998; Rabbani and Little, 1999; Katsura et al., 2002, 2005, 2007; Watson and Little, 2002; Rajadhyaksha and Kosofsky, 2005). Specifically, previous studies from our laboratory have demonstrated an enhancement of \(\alpha\)-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR) synaptic currents in hippocampal CA1 neurons (Van Sickle and Tietz, 2002; Song et al., 2007), which was associated with anxiety-like behavior in benzodiazepine-withdrawn rats (Van Sickle et al., 2004; Xiang and Tietz, 2007). Notably, acute systemic injection of the L-VGCC antagonist nimodipine, before AMPAR current enhancement, prevented both the augmentation of AMPAR currents in hippocampal CA1 neuron and anxiety-like behavior in benzodiazepine-withdrawn rats (Xiang and Tietz, 2007). These findings are consistent with other studies showing that administration of L-VGCC antagonists can interrupt withdrawal symptoms following benzodiazepine treatment (Gupta et al., 1996; El Ganouni et al., 2004; Cui et al., 2007), pointing to a role for regulation of L-VGCCs in mediating benzodiazepine dependence. However, little is known about the possible underlying mechanisms by which such adaptations may occur.

To investigate the means by which L-VGCCs could mediate benzodiazepine withdrawal phenomena, the properties of HVA Ca\(^{2+}\) currents were examined using whole-cell voltage-clamp techniques in hippocampal CA1 pyramidal neurons isolated from rats orally administered the water-soluble benzodiazepine flurazepam (FZP) for 1 week. The temporal pattern of changes in Ca\(^{2+}\) current density and activation kinetics was evaluated immediately and up to 4 days after drug withdrawal and in neurons from rats acutely administered desalkyl-FZP. In addition, the direct concentration- and use-dependent effect of the benzodiazepines to affect dihydropyridine (DHP) binding and HVA Ca\(^{2+}\) current density was evaluated in primary hippocampal culture. Finally, the ability of nimodipine preinjection to prevent the persistent enhancement AMPAR-mediated mEPSC amplitude was examined, to determine whether L-VGCCs not only initiate AMPAR current potentiation (Xiang and Tietz, 2007) but also play an additional role in maintaining current enhancement. Collectively, the findings suggest that chronic FZP administration transiently enhances L-VGCC function, which may serve to regulate intracellular calcium signaling and ultimately contribute to AMPAR plasticity and benzodiazepine withdrawal-anxiety. Modulation of VGCC function may relate to a direct interaction between benzodiazepines and HVA channels, in addition to the well known effects of the benzodiazepines at the GABA\(_A\) receptor.

**Materials and Methods**

**Protocols**

Experimental protocols involving the use of vertebrate animals were approved by the University of Toledo College of Medicine (formerly the Medical University of Ohio, Toledo, OH) Institutional Animal Care and Use Committee and conformed to National Institutes of Health guidelines.

**In Vivo Drug Treatments**

**Chronic Flurazepam Administration.** Oral FZP treatment of rats was as described previously (Van Sickle et al., 2004). In short, male Sprague-Dawley rats (initial age, postnatal day 22–25; Harlan, Indianapolis, IN) were offered only saccharin solution for a 2- to 4-day adaptation period. FZP dihydrochloride, pH 5.8, was then offered in 0.02% saccharin solution for 1 week as their only source of drinking water. The concentration of FZP was adjusted daily according to each rat’s body weight and fluid consumption (100 mg/kg × 3 days followed by 150 mg/kg × 4 days). Only rats that consumed a criterion dose of an average ≥120 mg/kg/day were accepted for study. At the end of drug administration, saccharin water was again provided for 0, 2, 3, or 4 days before hippocampal slice preparation on postnatal day 35 to 40 rats. Pair-handled, matched control rats receive saccharin water for the same length of time. Experimenters were blinded to rat treatment groups until the completion of the data analysis.

After this chronic FZP treatment, brain levels of residual FZP and its metabolites (1.2 μM) when expressed in DZP equivalents (0.6 μM) are similar to that of other common chronic benzodiazepine treatments (Gallagher et al., 1985; Xie and Tietz, 1992). Unlike in humans, brain levels of residual FZP and its metabolites decline rapidly over the first 24 h after drug removal and are no longer detectable in hippocampus in 2-day FZP-withdrawn rats (Xie and Tietz, 1992).

**Acute Desalkyl-FZP Administration.** To determine whether changes in hippocampal slices are specific to chronic BZ treatment, an acute dose of the primary active metabolite of FZP, desalkyl-FZP, was given to another group of rats. As described previously (Van Sickle and Tietz, 2002), desalkyl-FZP (2.5 mg/kg p.o.) was administered by gavage in an emulsion of peanut oil, water, and acacia (4:2:1). Rats were euthanized 30 min later for hippocampal slice preparation. Control rats received an equivalent volume of emulsion vehicle. The single dose of desalkyl-FZP was demonstrated previously by radioreceptor assay to result in levels of benzodiazepine activity similar to that found in rat hippocampus after 1-week FZP treatment, without a concomitant effect on GABA\(_A\) receptor-mediated inhibition (Xie and Tietz, 1992).

**Systemic L-VGCC Antagonist Injection.** Control and FZP-withdrawn rats were given a single intraperitoneal injection of nimodipine (10 mg/kg i.p.), an L-VGCC antagonist, or 2 ml/kg vehicle (0.5% Tween 80) 1 day after ending 1-week FZP treatment and 24 h before hippocampal slice preparation from 2-day FZP-withdrawn rats.

**Tissue Preparations**

**Acutely Isolated Hippocampal CA1 Pyramidal Neurons.** CA1 pyramidal neurons were acutely isolated using modifications of methods described previously (Van Sickle et al., 2002). Briefly, hippocampal slices, 400 μm were prepared on a Vibratome sectioning system (Ted Pella, Inc., Reading, CA) in ice-cold, preegassed (95% O\(_2\), 5% CO\(_2\)) buffer containing 120 mM NaCl, 2.5 mM KCl, 0.1 mM

Downloaded from jpet.aspetjournals.org at ASPET Journals on April 13, 2017
Neurons were voltage-clamped at a membrane holding potential stabilized for 10 min before current recording protocols were initiated. After establishing the whole-cell configuration, cells were allowed to converter and pClamp 9.2 acquisition software (Molecular Devices). 

lecular Devices, Sunnyvale, CA) using a Digidata 1200B AD/DA converter and pClamp 9.2 acquisition software (Molecular Devices). Current density (picoampere per picofarad) was defined as peak current amplitude divided by membrane capacitance and was plotted as a function of membrane potential (millivolts). Activation curves were constructed using individual conductance values for each cell using the equation $G = I/(V - V_h)$, where $V_h$ is the test voltage, $V_i$ is the cell reversal potential, and $I$ is the measured current (Sochivko et al., 2003). The current was then normalized to $G_{max}$, the maximal conductance. Inactivation curves were constructed by normalizing peak current amplitude to the maximal amplitude. The data points for the conductance, $G$ were fitted with a Boltzmann equation: $G_{max} = \frac{1}{1 + \exp[(V - V_0)/k]}$, where $G_{max}$ is the maximal $Ca^{2+}$ conductance, $V_0$ is the potential where $G$ was the half-maximal conductance, and $k$ is a factor proportional to the slope at $V_h$. Data points were normalized to the maximal conductance, averaged, and plotted. Inactivation curves were constructed by normalizing the current values to the largest value then fitted with the Boltzmann equation $IV(\max) = \frac{1}{1 + \exp[(V - V_h)/k]}$. 

**Use- and Concentration-Dependent Inhibition of $Ca^{2+}$ Currents.** The use- and concentration-dependent effect of FZP and DZP on whole-cell $HVA$ currents was assessed in 10 to 14 days in vitro (DIV) hippocampal cultured cells. A protocol modified from Reuveny et al., (1993) was used to deliver test pulses before and following a series of depolarizing trains delivered at several frequencies. After a 200-ms baseline test pulse (+10 mV from $V_h$ at −80 mV), trains of eight equivalent depolarizing pulses were delivered. Trains were applied at frequencies of 1, 2, 3, or 4 Hz followed within 10 ms by another test pulse. A recovery test pulse, without prior train stimulation was given at the end of the recording to exclude run-down of $Ca^{2+}$ channel function or seal degradation. The intertrain interval was >1 min to allow complete recovery from $Ca^{2+}$-dependent inactivation between trains. To study FZP effects on $HVA$ currents, the current density associated with each test pulse was evaluated in a train or no train condition, after 5-min preincubation with 1 μM FZP or vehicle in the external recording solution. $Ca^{2+}$ current density was normalized and expressed as the percentage of the current evoked by the baseline test pulse. To study concentration-dependent inhibition, benzodiazepine (0.1–100 μM) effects to inhibit $Ca^{2+}$ current were evaluated after 5-min preincubation in the external recording solution. $Ca^{2+}$ current was also studied in the presence or absence of DZP. The $Ca^{2+}$ current density was normalized and expressed as a percentage of current evoked in the presence of vehicle.

**AMPAR-Mediated mEPSC Recording.** AMPAR-mediated mEPSCs were recorded from CA1 neurons in ACSF plus 1 μM TTX, 50 μM picrotoxin, and 25 μM CGP-35348 using whole-cell voltage-clamp techniques (Xiang and Tietz, 2007). Patch pipettes (3–6 MΩ) were filled with internal solution containing 132.5 mM Cs methanesulfonate, 25 mM HEPES, and 25 μM CGP-35348 using whole-cell voltage-clamp techniques (Xiang and Tietz, 2007). Patch pipettes were inserted into the cell and the patch was pulled by a Narishige PC-10 holder. Local C-type current inhibition was monitored in the presence or absence of DZP. The Ca2+ current density was normalized and expressed as a percentage of current evoked in the presence of vehicle.
**Results**

HVA Ca\(^{2+}\) Currents in Acutely Isolated Hippocampal CA1 Pyramidal Neurons. To study Ca\(^{2+}\) channel function associated with FZP administration, HVA Ca\(^{2+}\) currents were recorded in acutely isolated hippocampal CA1 pyramidal neurons from rats after different lengths of FZP (or FZP metabolite) treatment and withdrawal. To isolate calcium currents, potassium currents were blocked with TEA, 4-AP, and Cs\(^{+}\) and sodium currents with TTX. Elicited currents were pharmacologically confirmed as predominantly L-type Ca\(^{2+}\) currents via inhibition with nimodipine (10 \(\mu\)M), a selective L-VGCC antagonist (Fig. 1B). The nimodipine-receptor effect on voltage-gated calcium currents 875 interaction associated with FZP administration, HVA Ca\(^{2+}\) currents were pharmacologically confirmed as predominantly L-type Ca\(^{2+}\) currents (Catterall, 2000). Figure 1, C and D, shows representative Ca\(^{2+}\) current traces elicited in

**Displacement of \([^{3}H]\) Dihydropyridine Binding**

The effect of benzodiazepines to inhibit DHP binding to L-VGCCs in homogenates of rat brain membranes was evaluated. Whole-brain homogenates (minus cerebellum and brain stem) were prepared as described previously (Xie and Tietz, 1992), except that the P2 pellet was initially incubated for 30 min at 37°C to remove ascorbic acid, and then tissues were freeze-thawed overnight and resuspended to a final concentration of 0.5 mg/ml as determined by bicinchoninic acid assay (Pierce Chemical, Rockford, IL). The reaction, initiated by addition of 320 \(\mu\)l of homogenate, was incubated for 90 min in a dimly lit room with 40 \(\mu\)l of 2 nM of the high-affinity DHP antagonist, \([^{3}H]\)PN200-110 in the presence or absence of increasing concentrations of nimodipine (10 pM to 1 mM) or FZP or DZP (1 nM to 1 mM) in 50 mM Tris-HCl buffer, pH 7.7, at room temperature. Non-specific binding was determined in the presence of 10 \(\mu\)M nitrendipine. The binding reaction was terminated by rapid vacuum filtration on number 32 glass fiber filters (Whatman Schleicher and Schuell, Keene, NH), followed by 3 \(\times\) 5 ml of ice-cold buffer washes. Filters were equilibrated overnight and counted 5 min in ScintiSafe 30% (Thermo Fisher Scientific, Waltham, MA).

**Statistical Comparisons.** Data are reported as mean ± S.E.M. Individual comparisons of Ca\(^{2+}\) current characteristics between experimental groups at each withdrawal period were by two-tailed unpaired Student's \(t\) test with Bonferroni's correction (Fig. 1B). The nimodipine-receptor effect on voltage-gated calcium currents 875

<table>
<thead>
<tr>
<th>Measure</th>
<th>Baseline</th>
<th>24h Withdrawal</th>
<th>4 Day Withdrawal</th>
<th>7 Day Withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capacitance (pF)</td>
<td>0.9 ± 0.2</td>
<td>0.8 ± 0.2</td>
<td>1.0 ± 0.2</td>
<td>1.0 ± 0.2</td>
</tr>
<tr>
<td>Current density (pA/pF)</td>
<td>2.0 ± 0.2</td>
<td>1.8 ± 0.2</td>
<td>2.0 ± 0.2</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>Activation voltage (mV)</td>
<td>-16.5 ± 0.2</td>
<td>-16.3 ± 0.2</td>
<td>-16.7 ± 0.2</td>
<td>-16.7 ± 0.2</td>
</tr>
<tr>
<td>Inactivation voltage (mV)</td>
<td>4.81 ± 0.2</td>
<td>4.81 ± 0.2</td>
<td>4.81 ± 0.2</td>
<td>4.81 ± 0.2</td>
</tr>
</tbody>
</table>

**Table 1**

Effects of chronic benzodiazepine administration and withdrawal on CA1 pyramidal neuron HVA Ca\(^{2+}\) currents

Values are mean ± S.E.M. Comparisons between FZP withdrawal groups and their matched controls were analyzed by a two-tailed unpaired Student's \(t\) test with Bonferroni's correction (Fig. 1B). The nimodipine-receptor effect on voltage-gated calcium currents 875

N.T., not tested.

* Significant difference, \(p < 0.05\).

**Benzodiazepine Effect on Voltage-Gated Calcium Currents**
neurons isolated from a control (CON) and a 2-day FZP-withdrawn rat (FZP), respectively.

**Temporal Regulation of HVA Ca\(^{2+}\) Currents.** The temporal pattern of changes in HVA channel function in CA1 neurons following acute treatment and after withdrawal from 1-week FZP treatment is summarized in Fig. 2 and Table 1. To demonstrate that enhanced HVA current density associated with FZP treatment was specific to protracted benzodiazepine exposure, an acute dose of the primary FZP-active metabolite, desalkyl-FZP (2.5 mg/kg p.o.), was given to one group of rats. This dose results in comparable benzodiazepine levels to that after 1-week FZP treatment (Van Sickle et al., 2004). Control rats received only the emulsion vehicle. There were no significant differences in Ca\(^{2+}\) current density in neurons from acute desalkyl-FZP-treated rats (\(n = 10\)) in comparison with controls (\(n = 10\)) (Fig. 2A). The current-voltage (I-V) curves generated in neurons from acutely treated rats and their controls were superimposable (Fig. 2A), similar to that illustrated after 4-day withdrawal in Fig. 2E.

The withdrawal periods examined after 1-week FZP administration precede and extend beyond the window of enhanced AMPAR glutamatergic strength associated with anxiety-like behavior (Van Sickle et al., 2004; Xiang and Tietz, 2007). I-V plots and peak current density in control neurons were similar to those described previously in dissociated CA1 neurons (Gorter et al., 2002) and were similar across all control groups (ANOVA, \(F = 2.1, \text{df} = 4, p = 0.09\)) (Fig. 2, A–E). There was a significant increase in Ca\(^{2+}\) current density in CA1 neurons isolated from rats immediately after (0-day) withdrawal from 1-week FZP treatment (\(n = 12, p < 0.05; \text{ANOVA}, F = 3.8, \text{df} = 9, p < 0.0002\)) compared with that from matched control rats (\(n = 10\)) (Fig. 2B). The increase in Ca\(^{2+}\) current density was sustained up to 2 days. That is, an equivalent increase in current density was found in neurons from 2-day FZP-withdrawn rats (\(n = 25; \*p < 0.01\)) in comparison with control neurons (\(n = 25\)) (Fig. 2C). Ca\(^{2+}\) current density was not significantly increased when examined in neurons from 3-day FZP-withdrawn rats (\(n = 18\)) (Fig. 2D) compared with matched control rats (\(n = 19; p > 0.05\)). After 4-day withdrawal, when AMPAR function has returned to baseline (Van Sickle et al., 2004), there were no significant differences in Ca\(^{2+}\) current density in FZP-withdrawn rats (\(n = 8; p > 0.05\)) in comparison with controls (\(n = 7\)) (Fig. 2E). The time course of changes in peak Ca\(^{2+}\) current density (\(V_{1/2} = 0 \text{ mV}\)) is illustrated in Fig. 2F.

---

**Table 2**

Effects of systemic nimodipine on CA1 pyramidal neuron mEPSC characteristics

<table>
<thead>
<tr>
<th>Group</th>
<th>RMP</th>
<th>mEPSC Characteristics</th>
<th>(\mu\text{A} \pm \sigma)</th>
<th>(\mu\text{A} \pm \sigma)</th>
<th>(\mu\text{A} \pm \sigma)</th>
<th>(\mu\text{A} \pm \sigma)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CON-VEH ((n = 8))</td>
<td>-61.0 ± 2.1</td>
<td>Frequency</td>
<td>0.26 ± 0.04</td>
<td>2.6 ± 0.5</td>
<td>8.5 ± 1.4</td>
<td>16.7 ± 2.8</td>
</tr>
<tr>
<td>FZP-VEH ((n = 8))</td>
<td>-61.0 ± 1.8</td>
<td>Rise Time</td>
<td>0.30 ± 0.07</td>
<td>2.8 ± 0.3</td>
<td>11.1 ± 0.9</td>
<td>15.6 ± 1.8</td>
</tr>
<tr>
<td>CON-NIM ((n = 7))</td>
<td>-61.4 ± 1.7</td>
<td>Amplitude</td>
<td>0.27 ± 0.06</td>
<td>2.5 ± 0.5</td>
<td>9.3 ± 1.5</td>
<td>16.3 ± 1.5</td>
</tr>
<tr>
<td>FZP-NIM ((n = 7))</td>
<td>-60.0 ± 1.9</td>
<td>(\tau)</td>
<td>-</td>
<td>-</td>
<td>9.0 ± 1.6</td>
<td>17.1 ± 2.1</td>
</tr>
</tbody>
</table>

ANOVA p > 0.05 p > 0.05 p > 0.05 p > 0.001 p > 0.05

CON, control; NIM, intraperitoneal injection of nimodipine; RMP, resting membrane potential; VEH, intraperitoneal injection of vehicle. \* \(p < 0.05\).
Voltage Dependence of Ca\textsuperscript{2+} Current Activation Is Altered after FZP Administration. Current amplitudes elicited by voltage steps from individual neurons were transformed to yield activation curves. Corresponding to the time course of the regulation of Ca\textsuperscript{2+} current density, there was a significant negative shift of the activation curve obtained from 0- and 2-day FZP-withdrawn rats compared with neurons from matched control rats (Fig. 3A). As shown in Table 1, the voltages of half-maximal activation (V\textsubscript{H}) were significantly (p = 0.008), negatively shifted (Fig. 3B) in neurons from 0-day FZP-withdrawn rats (n = 11) compared with their matched controls (n = 9; p < 0.05). This shift was also observed in neurons from 2-day FZP-withdrawn rats (n = 25) compared with their controls (n = 25; p < 0.001). There were no significant differences between the slopes of the activation curves between any FZP-withdrawn group and their matched control group (Fig. 3C). There were no differences in voltage dependence of Ca\textsuperscript{2+} current activation immediately after acute desalkyl-FZP, or 3 or 4 days after 1-week FZP treatment in comparison with controls (Table 1).

Voltage Dependence of Ca\textsuperscript{2+} Current Steady-State Inactivation Remained Unchanged. Representative steady-state inactivation traces from CA1 neurons isolated from a control and a 2-day FZP-withdrawn rat are shown in Fig. 4, B and C. As shown in Fig. 4D, inactivation curves were derived by fitting the Boltzmann function to Ca\textsuperscript{2+} currents elicited from individual neurons isolated from control and FZP-withdrawn rats. There were no significant shifts in the

---

Fig. 2. I-V relationship of HVA Ca\textsuperscript{2+} currents elicited from isolated CA1 neurons. Ca\textsuperscript{2+} currents were normalized by the membrane capacitance of individual neurons and are represented as current density (picampere per picofarad). A, for acute treatment, rats were similarly acclimated and offered saccharin water for 1 week followed by gavage (2.5 mg/kg p.o.) with the primary FZP metabolite desalkyl-FZP, a dose that results in comparable BZ levels to that after 1-week FZP treatment. Acute desalkyl-FZP treatment had no effect on Ca\textsuperscript{2+} current density (open circles, n = 10; *, p < 0.05) compared with that from matched control rats (closed circles, n = 10). B, there was a significant increase in Ca\textsuperscript{2+} current density in CA1 neurons isolated from rats immediately after (0-day) withdrawal from 1-week oral FZP-treatment (open circles, n = 12; *, p < 0.05) compared with that from matched control rats (close circles, n = 10). C, a similar increase in Ca\textsuperscript{2+} current density was found in neurons from 2-day FZP-withdrawn rats following 1-week FZP-treatment (open circles, n = 25; *, p < 0.05) in comparison with control neurons (closed circles, n = 25). D, this increase in Ca\textsuperscript{2+} current density was no longer significant when examined in neurons from rats treated 1-week with FZP and withdrawn for 3 days (closed circles, n = 9; *, p < 0.05) compared with matched control rats (open circles, n = 10). E, there were also no significant differences in Ca\textsuperscript{2+} current density in neurons from 4-day FZP-withdrawn rats (closed circles, n = 8; p > 0.05) in comparison with matched controls (open circles, n = 7). F, temporal pattern of changes in CA1 neuron HVA Ca\textsuperscript{2+} currents during acute and chronic FZP treatment and withdrawal. Peak Ca\textsuperscript{2+} current density at V\textsubscript{H} = 0 mV is shown. Acute, 0 days (CON: n = 10, closed bars; FZP: n = 10, open bars); 0 days (CON: n = 10, closed bars; FZP: n = 12, open bars); 2 days (CON: n = 25, closed bars; FZP: n = 25, open bars); 3 days (CON: n = 10, closed bars; FZP: n = 9, open bars); or 4 days (CON: n = 8, closed bars; FZP: n = 7, open bars) after ending 1-week FZP treatment.
inactivation curves from either 0- or 2-day FZP-withdrawn neurons compared with matched control neurons (Fig. 4D). As shown in Table 1, the voltages of half-maximal inactivation ($V_{1/2}$) were not significantly different from that of FZP-withdrawn rats compared with their matched control rats (Fig. 4E). There were also no significant differences in the slopes of the inactivation curves ($dV$) between the FZP-withdrawn groups and their matched control group (Fig. 4F). Because no changes in inactivation were noted in neurons from rats withdrawn at earlier time points, inactivation was not tested in neurons derived from 3- or 4-day FZP-withdrawn rats in which no other changes in HVA Ca$^{2+}$ currents were observed. There was no difference in the voltage dependence of Ca$^{2+}$ current steady-state inactivation immediately after acute desalkyl-FZP in comparison with their matched controls (Table 1).

**Low Potency of Benzodiazepines at [3H]Dihydropyridine Binding Sites.** One mechanism by which benzodiazepines might increase HVA Ca$^{2+}$ currents is by directly binding to and inhibiting L-VGCCs, possibly resulting in compensatory up-regulation of L-VGCC function. Such binding to L-VGCCs by benzodiazepines might be expected to disrupt the binding of conventional DHP L-VGCC antagonists. To evaluate whether FZP might directly inhibit L-VGCC function by binding to L-VGCCs, we measured, the ability of benzodiazepines to inhibit binding of the high-affinity DHP [3H]PN200-110 to rat brain synaptosomes in a Tris-Cl buffer in the absence of divalent and trivalent cations (Peterson and Catterall, 1995), which enhance positive cooperativity. As illustrated in Fig. 5, FZP exhibited weak concentration-dependent inhibition of specific [3H]PN200-110 binding (FZP $IC_{50}$ = 0.4 mM), whereas the prototype benzodiazepine, DZP, exhibited even lower potency ($IC_{50}$ = 1.3 mM). A nifedipine displacement curve was used as a standard for comparison. The benzodiazepines demonstrated 40- to 130-fold lower potency compared with nifedipine ($IC_{50}$ = 10.2 nM).

**Use- and Concentration-Dependent Inhibition of HVA Ca$^{2+}$ Current by FZP and DZP.** It was next important to determine whether benzodiazepines can inhibit HVA Ca$^{2+}$ currents and whether this occurs at physiologically relevant concentrations. The use- and concentration-dependent effects of benzodiazepines on HVA Ca$^{2+}$ currents were evaluated in DIV 10 to 14 hippocampal cultured cells. FZP (1 μM) had no effect on HVA Ca$^{2+}$ currents in hippocampal cultured neurons in which depolarizing pulses were not applied (VEH, $35.9 \pm 3.9\%$; FZP, $48.9 \pm 5.1\%; p > 0.05$) (Fig. 6, A and B). However, there was a slight run-down of HVA currents after repeated test pulses in the presence of vehicle. There were no differences between the benzodiazepines effect at the frequencies sampled (1–4 Hz); therefore, the inhibition data were averaged. In neurons in which consecutive depolarizing trains were applied, there was a significant inhibition of HVA Ca$^{2+}$ current density by 1 μM FZP compared with vehicle (VEH, $35.9 \pm 5.6\%$, $n = 4$; FZP, $20.3 \pm 2.4\%, n = 4$; $p < 0.05$). The progressive decline in HVA Ca$^{2+}$ currents with repeated stimulation probably represents Ca$^{2+}$-dependent inactivation of HVA currents after a train of consecutive depolarizing pulses as reported by Budde et al. (2002). The response returned to 94.7% of baseline upon recovery in the vehicle group and 67.4% in FZP group, suggesting the inhibition during depolarizing trains was not related the rundown of Ca$^{2+}$ channel function or seal degradation (Fig. 6, A and B).

The concentration-dependent effects of benzodiazepines on HVA Ca$^{2+}$ currents were also investigated. FZP and DZP (0.1–100 μM) inhibition of Ca$^{2+}$ current test pulses following depolarizing trains were evaluated after 5-min preincubation. As shown in Fig. 6C, both FZP and DZP (0.1–100 μM) inhibit HVA Ca$^{2+}$ currents in a concentration-dependent manner. The $IC_{50}$ value for FZP inhibition of Ca$^{2+}$ current was $\sim 2.0$ μM (log $IC_{50}$ = $-5.7 \pm 0.3$), with complete block of Ca$^{2+}$ currents at 100 μM FZP. DZP had a similar, but less potent, inhibitory effect on HVA Ca$^{2+}$ currents. The $IC_{50}$ value for DZP inhibition was $\sim 40$ μM (log $IC_{50}$ = $-4.4 \pm 0.2$), and 100 μM DZP inhibited only $\sim 75\%$ of the Ca$^{2+}$ current. The inhibition of Ca$^{2+}$ currents by the benzodiazepine antagonists was also similar in magnitude across each frequency
tested. The benzodiazepine antagonist flumazenil (1 μM) abolished 45.2 ± 11.4% of the Ca²⁺ current, whereas coapplication of 1 μM flumazenil and 1 μM DZP inhibited 48.0 ± 10.7% of the Ca²⁺ current, confirming that this inhibition is not mediated by action at the GABAA receptor benzodiazepine site.

Systemic Nimodipine Preinjection Prevents the Increase in AMPAR-Mediated mEPSCs in Neurons Isolated from 2-Day FZP-Withdrawn Rats. The time course of enhancement of HVA Ca²⁺ current preceded and overlapped the window of AMPAR plasticity. To examine whether L-VGCC-mediated Ca²⁺ influx might be involved in the enhanced AMPAR function associated with FZP withdrawal, L-VGCC activity was transiently interrupted by acute systemic injection of the L-VGCC antagonist nimodipine (10 mg/kg i.p.) at the beginning of FZP withdrawal, which previously was shown to block both the increase in AMPAR-mediated mEPSC amplitude (15–30%) and the associated FZP withdrawal-anxiety in 1-day FZP-withdrawn rats (Xiang and Tietz, 2007). Since the AMPAR-mediated mEPSC amplitude increases an additional 30 to 50% in 2-day FZP-withdrawn rats, it was important to determine whether nimodipine also blocked the later increase in mEPSC amplitude. To address this question, rats were injected systemically with nimodipine (10 mg/kg i.p.) or vehicle (0.5% Tween 80; 2 ml/kg i.p.) 1 day after FZP removal, and hippocampal slices were isolated 1 day later to evaluate AMPAR-mediated mEPSC characteristics. Figure 7A shows representative mEPSC current traces from neurons isolated from control and 2-day FZP-withdrawn rats. Figure 7B and Table 2 show that prior vehicle injection again had no effect on basal AMPAR mEPSC amplitude in control neurons or on
VGCCs play a major role in processes such as neurotransmitter release, synaptic plasticity, and gene expression (Catterall, 2000). The identified neuronal HVA Ca\(^{2+}\) channel subfamilies (L-, N-, P/Q-, and R-types) have different voltage activation thresholds and different physiological functions (Catterall, 2000; Lipscombe et al., 2004). To evaluate their functional role in benzodiazepine dependence, the properties of HVA Ca\(^{2+}\) currents were investigated in CA1 pyramidal neurons acutely isolated from rat hippocampus following acute and prolonged benzodiazepine treatment using whole-cell voltage-clamp techniques. HVA Ca\(^{2+}\) channel function developed in a time-dependent manner during prolonged benzodiazepine treatment and withdrawal (Fig. 2). A doubling of HVA Ca\(^{2+}\) current density was detectable immediately after ending 1-week FZP administration and was sustained for at least 2 days after ending treatment before tapering off 3 days after treatment. Concomitant with the increase in Ca\(^{2+}\) current density, there was a negative shift in the voltage dependence of Ca\(^{2+}\) channel activation in 0-day and 2-day FZP-withdrawn rats (Fig. 3) without a change in the voltage dependence of steady-state inactivation (Fig. 4). The time course of enhancement of HVA Ca\(^{2+}\) currents preceded and overlapped the transient increase in AMPAR-current potentiation, which was abolished by systemic nimodipine pretreatment. Collectively, the findings suggest that Ca\(^{2+}\) influx through L-VGCCs might contribute to the enhanced glutamatergic strength at CA1 neuron synapses associated with benzodiazepine withdrawal-anxiety (Van Sickle et al., 2004; Song et al., 2007; Xiang and Tietz, 2007).

Voltage-gated calcium channels have been reported to play role in neuronal plasticity (Morgan and Teyler, 1999; Shinnick-Gallagher et al., 2003; Yasuda et al., 2003, Bloodgood and Sabatini, 2008). Thus, the increase in the HVA current amplitude could be mediated by a change in the relative contribution of one or more calcium channel subtypes. Using selective toxins from wasp and spider venoms, at least five functional subtypes of HVA channels, including L-, N-, P/Q-, and R-types have been identified, and functional investigations into their role in neuronal plasticity have been complicated by their presence on both presynaptic terminals and postsynaptic dendrites (Catterall, 2000; Bloodgood and Sabatini, 2008). Both L- and R-type channels are involved in plasticity in CA1 neuron spines (Bloodgood and Sabatini, 2008). Moreover, multiple classes of Ca\(^{2+}\) channels including low-activated T-types contribute to postsynaptic Ca\(^{2+}\) entry in spines (R, L, and N) and dendrites (L and N) (Bloodgood and Sabatini, 2008). Both L- and R-type channels are involved in plasticity in CA1 neuron spines (Yasuda et al., 2003). Notwithstanding the range of possible Ca\(^{2+}\) channel subtypes that may be modulated in various models of activity-dependent plasticity, numerous investigations have suggested that disturbances of neuronal Ca\(^{2+}\) homeostasis, including enhanced Ca\(^{2+}\) entry associated with up-regula-

mEPSC enhancement during FZP withdrawal. However, transient interruption of L-VGCC activity following acute systemic nimodipine administration to 1-day FZP-withdrawn rats was sufficient to restore mean AMPAR mEPSC amplitude to control levels in CA1 neurons from 2-day FZP-withdrawn rats. As reported previously (Van Sickle et al., 2004; Xiang and Tietz, 2007), there were no differences in neuronal resting membrane potential, mEPSC frequency, rise time, or current decay between neurons from control versus FZP-withdrawn rats.

**Discussion**

VGCCs play a major role in processes such as neurotransmitter release, synaptic plasticity, and gene expression (Catterall, 2000). The identified neuronal HVA Ca\(^{2+}\) channel subfamilies (L-, N-, P/Q-, and R-types) have different voltage activation thresholds and different physiological functions (Catterall, 2000; Lipscombe et al., 2004). To evaluate their functional role in benzodiazepine dependence, the properties of HVA Ca\(^{2+}\) currents were investigated in CA1 pyramidal neurons acutely isolated from rat hippocampus following acute and prolonged benzodiazepine treatment using whole-cell voltage-clamp techniques. HVA Ca\(^{2+}\) channel function developed in a time-dependent manner during prolonged benzodiazepine treatment and withdrawal (Fig. 2). A doubling of HVA Ca\(^{2+}\) current density was detectable immediately after ending 1-week FZP administration and was sustained for at least 2 days after ending treatment before tapering off 3 days after treatment. Concomitant with the increase in Ca\(^{2+}\) current density, there was a negative shift in the voltage dependence of Ca\(^{2+}\) channel activation in 0-day and 2-day FZP-withdrawn rats (Fig. 3) without a change in the voltage dependence of steady-state inactivation (Fig. 4). The time course of enhancement of HVA Ca\(^{2+}\) currents preceded and overlapped the transient increase in AMPAR-current potentiation, which was abolished by systemic nimodipine pretreatment. Collectively, the findings suggest that Ca\(^{2+}\) influx through L-VGCCs might contribute to the enhanced glutamatergic strength at CA1 neuron synapses associated with benzodiazepine withdrawal-anxiety (Van Sickle et al., 2004; Song et al., 2007; Xiang and Tietz, 2007).

Voltage-gated calcium channels have been reported to play role in neuronal plasticity (Morgan and Teyler, 1999; Shinnick-Gallagher et al., 2003; Yasuda et al., 2003, Bloodgood and Sabatini, 2008). Thus, the increase in the HVA current amplitude could be mediated by a change in the relative contribution of one or more calcium channel subtypes. Using selective toxins from wasp and spider venoms, at least five functional subtypes of HVA channels, including L-, N-, P/Q-, and R-types have been identified, and functional investigations into their role in neuronal plasticity have been complicated by their presence on both presynaptic terminals and postsynaptic dendrites (Catterall, 2000; Bloodgood and Sabatini, 2008). Both L- and R-type channels are involved in plasticity in CA1 neuron spines (Bloodgood and Sabatini, 2008). Moreover, multiple classes of Ca\(^{2+}\) channels including low-activated T-types contribute to postsynaptic Ca\(^{2+}\) entry in spines (R, L, and N) and dendrites (L and N) (Bloodgood and Sabatini, 2008). Both L- and R-type channels are involved in plasticity in CA1 neuron spines (Yasuda et al., 2003). Notwithstanding the range of possible Ca\(^{2+}\) channel subtypes that may be modulated in various models of activity-dependent plasticity, numerous investigations have suggested that disturbances of neuronal Ca\(^{2+}\) homeostasis, including enhanced Ca\(^{2+}\) entry associated with up-regula-

**Fig. 6.** Use- and concentration-dependent inhibition of HVA Ca\(^{2+}\) current by benzodiazepines. The use- and concentration-dependent effect of benzodiazepines on HVA Ca\(^{2+}\) currents were evaluated in DIV 10 to 14 hippocampal cultured cells using whole-cell techniques. A, use-dependent effect of FZP on HVA Ca\(^{2+}\) currents. The Ca\(^{2+}\) current density was normalized and expressed as the percentage of the current evoked by baseline test pulse. Without a train of consecutive depolarizing pulses, 1 \(\mu M\) FZP showed little inhibitory effect on HVA Ca\(^{2+}\) current. Following train application at frequencies of 1, 2, 3, and 4 Hz, preincubation with 1 \(\mu M\) FZP resulted in approximately 45% inhibition by benzodiazepines on HVA Ca\(^{2+}\) currents. B, inhibition of HVA Ca\(^{2+}\) current by FZP. FZP (1 \(\mu M\)) had no effect on HVA Ca\(^{2+}\) currents in hippocampal cultured neurons in which depolarizing pulses were not applied (no trains: VEH, solid bar; FZP, open bar; \(p > 0.05\)). In neurons in which consecutive depolarizing trains were applied, 1 \(\mu M\) FZP inhibited had a similar effect to inhibit HVA Ca\(^{2+}\) currents across all frequencies sampled; therefore, these data were averaged (1–4-Hz trains: VEH, \(n = 4\); FZP, \(n = 4\); *; \(p < 0.05\)). C, concentration-dependent inhibition of HVA Ca\(^{2+}\) current by benzodiazepines. FZP and DZP (0.1–100 \(\mu M\)) effects to inhibit Ca\(^{2+}\) current test pulses were evaluated after 5-min preincubation. Ca\(^{2+}\) current density was normalized and expressed as the percentage of the current evoked in the presence of vehicle.
tion of L-type VGCC function, are involved in dependence on other central nervous system depressants such as ethanol, barbiturates, and morphine, as well as stimulants, including nicotine (Whittington and Little, 1993; Pourmotabbed et al., 1998; Rappani and Little, 1999; Katsura et al., 2002). The finding that chronic, but not acute, benzodiazepine administration enhances HVA Ca$^{2+}$ currents suggests that a similar effect may occur in hippocampal CA1 pyramidal neurons associated with benzodiazepine withdrawal symptoms (Van Sickle et al., 2004). Indeed, L-type calcium channel blockers such as nimodipine, nifedipine, and verapamil were reported to block a variety of benzodiazepine withdrawal signs (Gupta et al., 1996; El Ganouni et al., 2004). These studies raise the possibility of a potential role for L-VGCC activation in benzodiazepine dependence. Since a majority (87.2%; n = 2) of the HVA Ca$^{2+}$ current was blocked by 10 μM nimodipine (Fig. 1B) and 75% by 40 μM verapamil (data not shown), enhanced L-VGCC function probably contributes significantly to HVA current enhancement. However, a contribution from other HVA channels (N-, P/Q-, and R-type) cannot be excluded, and their roles in mediating benzodiazepine dependence remain to be elucidated.

Consistent with these findings, chronic benzodiazepine administration was reported to increase the number of DHP-sensitive binding sites (Brennan and Littleton, 1991; Katsura et al., 2007). More recently, increased expression of L-VGCC subunits, including the α1C (Ca$_{\alpha,1.2a1}$) and α1D (Ca$_{\alpha,1.3c1}$) subtypes, and associated α2/δ1 subtypes, was demonstrated in vitro after chronic exposure to benzodiazepines. Increased subunit expression was also demonstrated in vivo in physically dependent mice (Katsura et al., 2007). In single CA1 neurons, increased Ca$_{\alpha,1.3c1}$ subunit transcript levels were positively correlated with increased VGCC activity (Chen et al., 2000). Because Ca$_{\alpha,1.3c1}$-containing channels activate at potentials approximately 20 to 25 mV more hyperpolarized in comparison with Ca$_{\alpha,1.2a1}$-containing channels (Xu and Lipscombe, 2001; Lipscombe et al., 2004), an increase in Ca$_{\alpha,1.3c1}$ subunit protein in the CA1 region could explain both the increased current density and the negative shift in voltage dependence of Ca$^{2+}$ current activation (Fig. 3). Yet, it is also known that Ca$_{\alpha,1.2a1}$-containing channels couple membrane depolarization to regulation of gene expression and to a variety Ca$^{2+}$-mediated phosphorylation/dephosphorylation pathways that contribute to synaptic plasticity (Dolmetsch et al., 2001; Rajadhyaksha and Kosofsky, 2005). Therefore, modulation of the Ca$_{\alpha,1.2a1}$ subunit levels or phosphorylation state may also be involved in the HVA current enhancement. It will be of significant interest to investigate the expression of Ca$_{\alpha,1.2a1}$ and Ca$_{\alpha,1.3c1}$ subunit proteins in hippocampal CA1 region in FZP-withdrawn rats in relation to changes in L-VGCC single-channel function.

Importantly, increased DHP-binding site number and increased expression of L-VGCC Ca$_{\alpha,1.2a1}$ and Ca$_{\alpha,1.3c1}$ subunits were also demonstrated in animals physically dependent on ethanol, morphine, or nicotine (Katsura et al., 2002, 2005; Hayashida et al., 2005; Shibasaki et al., 2007). Increases in expression of specific L-type channel subunits associated with enhanced HVA Ca$^{2+}$ channel function may provide a common mechanism underlying dependence on and addiction to a variety of drugs of abuse.

Although the precise mechanisms related to the negative shift in voltage dependence of Ca$^{2+}$ current activation re-
mains to be elucidated, this shift may have significant physiological importance following chronic benzodiazepine administration. As a consequence of prolonged GABA<sub>A</sub> receptor activation during FZP administration, numerous time-dependent changes occur at the GABA<sub>A</sub> receptor. Some of these changes may measurably influence CA1 neuron hyperexcitability (Van Sickle et al., 2004), including a bicarbonate-driven Cl<sup>-</sup> accumulation reflected in a shift in the Cl<sup>-</sup> reversal potential and the appearance of a bicuculline-sensitive depolarizing potential (Zeng et al., 1995; Zeng and Tietz, 1997, 1999). Lower threshold L-VGCCs, such as Ca<sub>L.3ca1</sub>-containing channels, would more likely be activated by these fast, subthreshold depolarizing driving forces and trigger Ca<sup>2+</sup> influx. In fact, several studies have shown an increased accumulation of intracellular calcium through L-VGCCs following prolonged GABA<sub>A</sub> receptor activation that leads to bicarbonate-driven Cl<sup>-</sup> entry and Cl<sup>-</sup> accumulation (Reichling et al., 1994; Marty and Llano, 2005).

In addition to their well-characterized effects at GABA<sub>A</sub> receptors, benzodiazepines were reported previously to inhibit neuronal VGCC-mediated Ca<sup>2+</sup> flux (Taft and DeLorenzo, 1984; Reuveny et al., 1993; Ishizawa et al., 1997). Micromolar benzodiazepine binding sites were proposed to mediate benzodiazepine inhibition of depolarization-dependent Ca<sup>2+</sup> uptake into synaptosomes, suggesting that diazepam brain concentrations achieved during intravenous administration for status epilepticus (>10 μM) may be sufficient to block L-type VGCCs (Taft and DeLorenzo, 1984). Both FZP (IC<sub>50</sub> = 0.4 mM) and DZP (IC<sub>50</sub> = 1.3 mM) had weak potency to inhibit [H<sup>3</sup>]/PN200-110 binding to DHP binding sites (Fig. 5). Nonetheless, the potency of FZP (IC<sub>50</sub> of ~2 μM) and DZP (IC<sub>50</sub> of ~40 μM) to inhibit Ca<sup>2+</sup> current in hippocampal cultures was significantly greater when Ca<sup>2+</sup> channels were activated by a prior depolarizing train (Fig. 6), suggesting that benzodiazepine inhibition of VGCC-mediated currents is use-dependent, as shown previously with chloridiazepoxide (Reuveny et al., 1993). Oral flurazepam treatment of rats and other common diazepam treatment routes result in rat brain levels of benzodiazepine metabolites in the low micromolar range (1.2 μM flurazepam equivalents; 0.6 μM in diazepam equivalents) (Xie and Tietz, 1992). Thus, the low micromolar benzodiazepine brain levels attained during chronic treatment would be expected to have their primary action on GABA<sub>A</sub> receptors but could also have prominent actions to interact with HVA channels. However, it is unlikely that the actions of the benzodiazepines to inhibit Ca<sup>2+</sup> channels would result in up-regulation of L-VGCCs since chronic nimodipine reduces Ca<sub>L.3ca1</sub> subunit expression in hippocampus (Veng et al., 2003). Thus, it is possible that a secondary, opposing effect of the benzodiazepines to inhibit Ca<sup>2+</sup> channels could lessen an effect of GABA depolarization to enhance L-VGCC expression. Alternatively, the ability of benzodiazepines to inhibit Ca<sup>2+</sup> channels during drug elimination from brain, up to 1 day after ending treatment (t<sub>1/2</sub> = <12 h) could contribute to the delay in the appearance of AMPAR potentiation and withdrawal symptoms.

Notably, the temporal pattern of modifications of HVA Ca<sup>2+</sup> currents (Fig. 2F) preceded and overlapped the window of AMPAR synaptic plasticity, demonstrated previously to correlate with benzodiazepine withdrawal-anxiety in rats (Van Sickle et al., 2004; Xiang and Tietz, 2007). These findings suggest that HVA Ca<sup>2+</sup> channels, rather than N-methyl-D-aspartate receptors (Van Sickle et al., 2004), may serve as an important source of Ca<sup>2+</sup>-mediating hippocampal CA1 neuron hyperexcitability and synaptic plasticity associated with withdrawal-anxiety. Activation of neuronal HVA Ca<sup>2+</sup> channels triggers a transient influx of Ca<sup>2+</sup> upon depolarization that, via diverse soluble messengers and transcription factors, initiates long-term processes related to synaptic plasticity in the hippocampus and amygdala (Dolmetsch et al., 2001). L-type VGCCs and N-methyl-D-aspartate receptors underlie two forms of long-term potentiation in hippocampal CA1 neurons in vivo (Morgan and Teylor, 1999). In midbrain striatal dopamine pathways, activation of L-VGCC calcium influx is proposed to activate downstream Ca<sup>2+</sup>/calmodulin-activated kinase and phosphatase pathways, eventually involving cAMP response element-binding protein-induced gene expression, and psychostimulant-induced plasticity (Nestler, 2005; Rajadhyaksha and Kosofsky, 2005). The finding that prior systemic injection of the L-type VGCC agonist nimodipine averted the up-regulation of CA1 neuron AMPAR function in 2-day FZP-withdrawn rats (Fig. 7), even after functional up-regulation of AMPARs in 1-day FZP-withdrawn rats, suggests that AMPAR regulation may be a dynamic process dependent on a sustained rise in intracellular Ca<sup>2+</sup> during the FZP withdrawal period. The effect was not through a direct interaction between the antagonist and AMPARs, because nimodipine had no direct effect on AMPAR-mediated mEPSCs (Xiang and Tietz, 2007). These findings may also explain the ability of L-type calcium channel blockers to block a variety of benzodiazepine withdrawal signs, including hyperkinesia, hyperthermia, hyperaggression, and audiogenic seizures (Gupta et al., 1996; El Ganouni et al., 2004). The accumulated evidence supports the possibility that L-type VGCCs may be a major Ca<sup>2+</sup> source for diverse intracellular messengers or transcription factors to increase glutamatergic strength during benzodiazepine withdrawal and contribute to benzodiazepine physical dependence.

Previous studies in FZP-withdrawn rats demonstrated that hippocampal CA1 neuron AMPAR-mediated hyperexcitability is an essential component of a functional anatomic circuit associated with expression of benzodiazepine withdrawal-anxiety (Xiang and Tietz, 2007). Coupled with the previous findings, the evidence provided in this report suggests that chronic benzodiazepine treatment and withdrawal enhances HVA Ca<sup>2+</sup> channel function in a transitory manner preceding the potentiation of AMPAR function and may be central to CA1 neuron AMPAR synaptic plasticity and benzodiazepine physical dependence. Altered L-type VGCC-mediated Ca<sup>2+</sup> homeostasis may also serve as a generalized mechanism for underlying physical dependence to a variety of drugs of abuse and may serve as a common site for pharmacological interventions to prevent withdrawal phenomena.

Acknowledgments

We thank Paromita Das, Krista Pettee, Brian Behrle, and William Ferencak, III, for expert contributions to this work.

References


Brennan CH and Littleton JM (1991) Chronic exposure to anxiolytic drugs, working


Veng LM, Mesches MH, and Browning MD (2003) Age-related working memory impairment is correlated with increases in the L-type calcium channel protein alpha1D (Cav1.3) in area CA1 of the hippocampus and both are ameliorated by chronic morphine treatment. J Neurosci 23:9479–9485.


Address correspondence to: Dr. Elizabeth I. Tietz, Department ofPhysiology and Pharmacology, University of Toledo College of Medicine (formerly Medical University of Ohio), University of Toledo Health Science Campus, 9000 West Bancroft Ave., Mailstop 1008, Toledo, OH 43614. E-mail: Liz.tietz@utoledo.edu.